Apollomics Cost Of Revenue from 2010 to 2026

APLM Stock   19.79  0.59  3.07%   
Apollomics Cost Of Revenue yearly trend continues to be very stable with very little volatility. Cost Of Revenue is likely to grow to about 639.6 K this year. During the period from 2010 to 2026, Apollomics Cost Of Revenue quarterly data regression pattern had sample variance of 22 B and median of  369,000. View All Fundamentals
 
Cost Of Revenue  
First Reported
2010-12-31
Previous Quarter
415.1 K
Current Value
639.6 K
Quarterly Volatility
148.3 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Apollomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Apollomics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 61.6 K, Interest Expense of 114.2 K or Gross Profit of 216.3 K, as well as many indicators such as Price To Sales Ratio of 49.84, Dividend Yield of 0.0 or PTB Ratio of 1.75. Apollomics financial statements analysis is a perfect complement when working with Apollomics Valuation or Volatility modules.
  
Build AI portfolio with Apollomics Stock
Check out the analysis of Apollomics Correlation against competitors.
Evaluating Apollomics's Cost Of Revenue across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Apollomics Class A's fundamental strength.

Latest Apollomics' Cost Of Revenue Growth Pattern

Below is the plot of the Cost Of Revenue of Apollomics Class A over the last few years. Cost of Revenue is found on Apollomics Class A income statement and represents the costs associated with goods and services Apollomics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities. It is Apollomics' Cost Of Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Apollomics' overall financial position and show how it may be relating to other accounts over time.
Cost Of Revenue10 Years Trend
Slightly volatile
   Cost Of Revenue   
       Timeline  

Apollomics Cost Of Revenue Regression Statistics

Arithmetic Mean462,635
Geometric Mean443,689
Coefficient Of Variation32.05
Mean Deviation127,703
Median369,000
Standard Deviation148,282
Sample Variance22B
Range414K
R-Value0.59
Mean Square Error15.2B
R-Squared0.35
Significance0.01
Slope17,415
Total Sum of Squares351.8B

Apollomics Cost Of Revenue History

2026639.6 K
2025415.1 K
2024361 K
2023694 K
2022775 K
2021681 K
2020609 K

About Apollomics Financial Statements

Apollomics investors utilize fundamental indicators, such as Cost Of Revenue, to predict how Apollomics Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Cost Of Revenue415.1 K639.6 K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Apollomics Class A is a strong investment it is important to analyze Apollomics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Apollomics' future performance. For an informed investment choice regarding Apollomics Stock, refer to the following important reports:
Check out the analysis of Apollomics Correlation against competitors.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Will Biotechnology sector continue expanding? Could Apollomics diversify its offerings? Factors like these will boost the valuation of Apollomics. If investors know Apollomics will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Apollomics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(52.80)
Revenue Per Share
0.194
Quarterly Revenue Growth
2.623
Return On Assets
(0.75)
Return On Equity
(2.34)
The market value of Apollomics Class A is measured differently than its book value, which is the value of Apollomics that is recorded on the company's balance sheet. Investors also form their own opinion of Apollomics' value that differs from its market value or its book value, called intrinsic value, which is Apollomics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Apollomics' market value can be influenced by many factors that don't directly affect Apollomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Apollomics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Apollomics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Apollomics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.